CureVac (CVAC) Stock Price
CureVac Price
Over the last 6 years CureVac grew revenue by 86.1% annually, reaching 535.18 M EUR. For CureVac, the net margin of 30.3% is up versus -264.0% a few years ago. The consensus 12-month price target for CureVac is 4.82 EUR, about 18.2% above where the stock trades today. Of 11 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 13% above its 52-week low.
CureVac stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CureVac over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CureVac stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CureVac's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CureVac Price |
|---|---|
| 1/5/2026 | 4.08 EUR |
| 1/2/2026 | 4.08 EUR |
| 12/31/2025 | 3.95 EUR |
| 12/30/2025 | 3.92 EUR |
| 12/29/2025 | 3.78 EUR |
| 12/26/2025 | 3.76 EUR |
| 12/24/2025 | 3.77 EUR |
| 12/23/2025 | 3.68 EUR |
| 12/22/2025 | 3.60 EUR |
| 12/19/2025 | 3.64 EUR |
| 12/18/2025 | 3.74 EUR |
| 12/17/2025 | 3.61 EUR |
| 12/16/2025 | 4.22 EUR |
| 12/15/2025 | 4.37 EUR |
| 12/12/2025 | 4.42 EUR |
| 12/11/2025 | 4.48 EUR |
| 12/10/2025 | 4.47 EUR |
| 12/9/2025 | 4.48 EUR |
| 12/8/2025 | 4.56 EUR |
| 12/5/2025 | 4.48 EUR |
| 12/4/2025 | 4.48 EUR |
| 12/3/2025 | 4.51 EUR |
| 12/2/2025 | 4.47 EUR |
| 12/1/2025 | 4.55 EUR |
| 11/28/2025 | 4.80 EUR |
| 11/26/2025 | 4.79 EUR |
| 11/25/2025 | 4.62 EUR |
| 11/24/2025 | 4.47 EUR |
| 11/21/2025 | 4.40 EUR |
| 11/20/2025 | 4.48 EUR |
| 11/19/2025 | 4.57 EUR |
| 11/18/2025 | 4.57 EUR |
| 11/17/2025 | 4.62 EUR |
| 11/14/2025 | 4.62 EUR |
| 11/13/2025 | 4.64 EUR |
| 11/12/2025 | 4.67 EUR |
| 11/11/2025 | 4.62 EUR |
| 11/10/2025 | 4.57 EUR |
| 11/7/2025 | 4.56 EUR |
| 11/6/2025 | 4.59 EUR |
| 11/5/2025 | 4.61 EUR |
| 11/4/2025 | 4.64 EUR |
| 11/3/2025 | 4.67 EUR |
| 10/31/2025 | 4.67 EUR |
| 10/30/2025 | 4.69 EUR |
| 10/29/2025 | 4.71 EUR |
| 10/28/2025 | 4.70 EUR |
| 10/27/2025 | 4.71 EUR |
| 10/24/2025 | 4.69 EUR |
| 10/23/2025 | 4.71 EUR |
| 10/22/2025 | 4.71 EUR |
| 10/21/2025 | 4.70 EUR |
| 10/20/2025 | 4.69 EUR |
| 10/17/2025 | 4.69 EUR |
| 10/16/2025 | 4.70 EUR |
| 10/15/2025 | 4.72 EUR |
| 10/14/2025 | 4.69 EUR |
| 10/13/2025 | 4.71 EUR |
| 10/10/2025 | 4.71 EUR |
| 10/9/2025 | 4.73 EUR |
| 10/8/2025 | 4.74 EUR |
| 10/7/2025 | 4.75 EUR |
| 10/6/2025 | 4.73 EUR |
| 10/3/2025 | 4.77 EUR |
| 10/2/2025 | 4.71 EUR |
| 10/1/2025 | 4.72 EUR |
| 9/30/2025 | 4.71 EUR |
| 9/29/2025 | 4.68 EUR |
| 9/26/2025 | 4.70 EUR |
| 9/25/2025 | 4.68 EUR |
| 9/24/2025 | 4.69 EUR |
| 9/23/2025 | 4.69 EUR |
| 9/22/2025 | 4.69 EUR |
| 9/19/2025 | 4.68 EUR |
| 9/18/2025 | 4.68 EUR |
| 9/17/2025 | 4.69 EUR |
| 9/16/2025 | 4.68 EUR |
| 9/15/2025 | 4.69 EUR |
| 9/12/2025 | 4.67 EUR |
| 9/11/2025 | 4.71 EUR |
| 9/10/2025 | 4.71 EUR |
| 9/9/2025 | 4.71 EUR |
| 9/8/2025 | 4.68 EUR |
| 9/5/2025 | 4.71 EUR |
| 9/4/2025 | 4.68 EUR |
| 9/3/2025 | 4.69 EUR |
| 9/2/2025 | 4.70 EUR |
| 8/29/2025 | 4.70 EUR |
| 8/28/2025 | 4.70 EUR |
| 8/27/2025 | 4.71 EUR |
| 8/26/2025 | 4.72 EUR |
| 8/25/2025 | 4.72 EUR |
| 8/22/2025 | 4.76 EUR |
| 8/21/2025 | 4.74 EUR |
| 8/20/2025 | 4.77 EUR |
| 8/19/2025 | 4.78 EUR |
| 8/18/2025 | 4.77 EUR |
CureVac Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CureVac Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.00 | 17.00 | 48.00 | 102.00 | 67.00 | 53.00 | 535.00 | – | 88.00 | 151.00 | 201.00 | 253.00 | 293.00 |
| – | 41.67 | 182.35 | 112.50 | -34.31 | -20.90 | 909.43 | – | – | 71.59 | 33.11 | 25.87 | 15.81 |
| -33.33 | -58.82 | 70.83 | -132.35 | -173.13 | -132.08 | 80.19 | – | 80.19 | 80.19 | 80.19 | 80.19 | 80.19 |
| -4.00 | -10.00 | 34.00 | -135.00 | -116.00 | -70.00 | 429.00 | 429.00 | 70.56 | 121.08 | 161.18 | 202.87 | 234.95 |
| -72.00 | -99.00 | -136.00 | -422.00 | -249.00 | -274.00 | 177.00 | -137.00 | -97.00 | -58.00 | 49.00 | 99.00 | 135.00 |
| -600.00 | -582.35 | -283.33 | -413.73 | -371.64 | -516.98 | 33.08 | – | -110.23 | -38.41 | 24.38 | 39.13 | 46.08 |
| -71.00 | -99.00 | -129.00 | -411.00 | -249.00 | -260.00 | 162.00 | -121.00 | -111.00 | -21.00 | -122.00 | -124.00 | – |
| – | 39.44 | 30.30 | 218.60 | -39.42 | 4.42 | -162.31 | -174.69 | -8.26 | -81.08 | 480.95 | 1.64 | – |
| 224.34 | 175.97 | 180.46 | 180.46 | 189.07 | 223.99 | 224.34 | 224.34 | 224.34 | 224.34 | 224.34 | 224.34 | 224.34 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CureVac generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CureVac retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CureVac's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CureVac has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CureVac's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CureVac stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CureVac Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CureVac business model & stock analysis
CureVac SWOT Analysis
Strengths
- Strong research and development capabilities, enabling innovation and development of potential breakthrough mRNA-based therapies and vaccines.
- Broad and diverse pipeline of product candidates, providing potential for growth in different therapeutic areas.
- Strategic partnerships and collaborations with leading pharmaceutical companies, enhancing the company's research, development, and commercialization capabilities.
Weaknesses
- Dependence on the success of mRNA platform technology, which is a relatively new and evolving field with potential regulatory and technical challenges.
- Limited commercial experience and lack of a marketed product, posing risks in terms of revenue generation and market acceptance.
- Reliance on a few key product candidates, making the company vulnerable to potential failures or delays in clinical trials.
Opportunities
- Increasing demand for mRNA-based therapies and vaccines, driven by advancements in personalized medicine and the need for innovative treatment options.
- Expansion into new therapeutic areas and global markets, leveraging partnerships, collaborations, and potentially licensing agreements.
- Potential for strategic alliances with governments, organizations, or research institutions to accelerate development and distribution of mRNA-based vaccines during global health crises.
Threats
- Intense competition in the mRNA-based therapeutics field, with established and emerging biopharmaceutical companies vying for market share.
- Uncertainties related to clinical trial outcomes, regulatory approvals, and intellectual property rights, which could impact the company's ability to bring products to market.
- Economic and regulatory factors, such as pricing pressures, reimbursement policies, and changing healthcare systems, that may impact product commercialization and profitability.
CureVac Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
CureVac historical P/E ratio, EBIT multiple, and P/S ratio
CureVac annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CureVac shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
CureVac stock splits
Current CureVac forecasts and price targets in August 2026
Analyst Price Targets 2026CureVac Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/8/2026 | 0.05EUR | - | 44.78 MEUR | - | 2025 Q4 |
| 11/18/2025 | -0.11EUR | - | 10.91 MEUR | - | 2025 Q3 |
| 8/13/2025 | -0.19EUR | - | 35.28 MEUR | - | 2025 Q2 |
| 11/14/2024 | 0.57EUR | - | 105.84 MEUR | - | 2024 Q3 |
| 5/21/2024 | -0.17EUR | - | 15.31 MEUR | - | 2024 Q1 |
| 4/23/2024 | -0.20EUR | - | 27.99 MEUR | - | 2023 Q4 |
| 11/14/2023 | -0.27EUR | - | -EUR | - | 2023 Q3 |
| 4/26/2023 | -0.29EUR | - | 21.14 MEUR | - | 2022 Q4 |
| 11/16/2022 | -0.27EUR | - | 20.64 MEUR | - | 2022 Q3 |
| 8/18/2022 | -0.26EUR | - | 18.27 MEUR | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the CureVac stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
CureVac shareholder structure
| % | Name |
|---|---|
13.26617% | |
7.36863% | |
0.87542% | |
0.52496% | |
0.42503% | |
0.26418% |
CureVac Executives and Management Board
12 members · avg. age 60 · 25 % women
Dr. Alexander Zehnder (55)
Chief Executive Officer, Member of the Management Board
929,699.00 EUR
Management
Dr. Myriam Mendila (58)
Chief Scientific Officer, Member of the Management Board
Dr. Malte Greune (60)
Chief Operating Officer, Member of the Management Board
Mr. Thaminda Ramanayake (48)
Chief Business Officer, Member of the Management Board
Mr. Axel-Sven Malkomes (58)
Chief Financial Officer
Board of Directors
Mr. Baron Stephenne (75)
Independent Chairman of Supervisory Board · since 2015
Dr. Mathias Hothum (57)
Member of the Supervisory Board
Mr. Craig Tooman (59)
Independent Member of the Supervisory Board
Mr. Michael Brosnan (70)
Independent Member of the Supervisory Board
Dr. Debra Barker (63)
Member of the Supervisory Board
Dr. Klaus Schollmeier (68)
Independent Member of the Supervisory Board
Frequently asked questions about CureVac
Some of the main competitors of CureVac NV in the market are Moderna Inc., BioNTech SE, and Pfizer Inc. These companies also specialize in the development of mRNA-based therapeutics and vaccines. However, CureVac NV differentiates itself through its proprietary RNAoptimizer platform, which enables efficient, scalable, and cost-effective mRNA production. With its innovative technology and a strong pipeline of candidates, CureVac NV aims to create a significant presence in the market.
The business model of CureVac NV focuses on the development of transformative messenger RNA (mRNA) therapeutics and vaccines. By leveraging its proprietary mRNA platform, CureVac aims to address various diseases and medical conditions across multiple therapeutic areas, including infectious diseases, oncology, and rare diseases. Their mRNA technology allows for the production of vaccine candidates and therapeutic proteins, which can be customized to target specific diseases. This innovative approach offers potential advantages such as rapid development, scalability, and adaptability. As a leading biopharmaceutical company, CureVac NV seeks to revolutionize the field of medicine through the use of mRNA to provide innovative treatment options for patients worldwide.
CureVac NV is primarily active in the biotechnology industry.
CureVac NV is a biopharmaceutical company specializing in developing messenger RNA (mRNA) therapeutics and vaccines. Founded in 2000, CureVac has a rich history of groundbreaking mRNA research. The company is headquartered in Tübingen, Germany, and has expanded its presence globally, including the establishment of CureVac Inc. in the United States. CureVac has pioneered the use of mRNA as a platform for various therapeutic applications, including cancer treatments, infectious diseases, and rare diseases. As a leading player in the field, CureVac has collaborated with numerous strategic partners and received significant funding for its innovative mRNA technology, demonstrating its promising potential in revolutionizing the medical industry.
CureVac NV, a renowned biopharmaceutical company, has attained several significant milestones in its journey. Notably, CureVac NV successfully completed its initial public offering (IPO) in August 2020, raising substantial capital for its research and development activities. Moreover, the company has made noteworthy advancements in the development of mRNA-based vaccines and therapeutics, showcasing promising results in preclinical and clinical trials. CureVac NV has also established strategic partnerships with various leading pharmaceutical companies, such as Bayer, GSK, and the Bill & Melinda Gates Foundation, further strengthening its research and commercialization capabilities. With its pioneering approach and collaborative efforts, CureVac NV continues to revolutionize the field of mRNA-based healthcare solutions.
CureVac NV is primarily present in various countries and regions. The company's presence spans across Europe, including Germany, Switzerland, and Austria, where its headquarters and research facilities are located. CureVac NV also has a strong presence in the United States, with operations in Cambridge, Massachusetts. The company's global expansion efforts have led to its presence in other regions, such as Latin America, Africa, and Asia, as it collaborates with partners and conducts clinical trials worldwide. With its widespread presence and international collaborations, CureVac NV is dedicated to advancing mRNA-based technologies and developing innovative solutions on a global scale.
CureVac NV represents a commitment to transforming the lives of patients through groundbreaking mRNA technology. With a strong corporate philosophy centered on innovation, quality, and collaboration, the company strives to develop and deliver mRNA-based therapeutics and vaccines to address a wide range of diseases, including cancer and infectious diseases. CureVac NV's values are built upon scientific excellence, patient-centricity, and sustainability. By harnessing the power of mRNA, the company aims to revolutionize healthcare and improve global health outcomes. Through continuous research and strategic partnerships, CureVac NV demonstrates its dedication to advancing the field of mRNA-based medicine and making a positive impact on society.
Analysts currently set an average price target of 4.82 EUR for the CureVac stock (median: 4.82 EUR), implying +18.2 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the CureVac stock: 6 recommend buying, 5 holding and 0 selling. For 2026, analysts expect CureVac to generate revenue of 88.19 M EUR and earnings per share of -0.50 EUR.
The CureVac share (CVAC) is listed on 10 stock exchanges, including: NASDAQ (CVAC), XETRA (5CV.DE), Frankfurt (5CV.F), München (5CV.MU), Düsseldorf (5CV.DU), Hamburg (5CV.HM), London (0A9E.L), SIX (Zürich) (5CV.SW).
CureVac NV is a biotechnology company based in Tübingen, specializing in the development of mRNA-based therapies and vaccines. The company's business model is based on basic research and the development of innovative technologies for the production of mRNA-based products. One of CureVac's key areas is the development of mRNA vaccines. The company uses its platform technology to produce mRNA molecules that stimulate the body's immune system and induce a protective immune response. CureVac has already developed several vaccine candidates for diseases such as COVID-19 and cancer, which are currently in clinical development. Another focus of the company is the development of mRNA therapies. This involves using mRNA technology to produce therapeutic proteins or antibodies in the body to treat diseases. CureVac's therapy areas include cancer, rare diseases, and infectious diseases. To develop and manufacture these technologies, CureVac has its own research and development as well as production facilities. The company utilizes mRNA technology to produce clinical and commercial quantities of mRNA products. CureVac follows a highly automated and standardized production process to ensure high quality and large quantities of products. Collaboration with industry and scientific partners is also an important part of CureVac's business model. The company has formed partnerships with various pharmaceutical companies to jointly work on the development of mRNA-based therapies and vaccines. Additionally, CureVac works closely with universities and research institutions to advance basic research on mRNA technology. To expand the applications of its technology, CureVac continuously invests in researching new mRNA platforms and developing new technologies to improve the delivery of mRNA products in the body. This will allow for effective treatment of a wider range of diseases. In summary, CureVac's business model is based on the development and application of mRNA technology for the production of therapeutic proteins, antibodies, and vaccines. The company engages in both research and development activities and operates its own production facility, while collaborating with industry and scientific partners. With the use of its platform technology and continuous innovation, CureVac aims to effectively treat a wider range of diseases.
The expected revenue of CureVac is 88.19 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CureVac is -111.86 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CureVac is currently -8.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CureVac stock.
The price-to-sales ratio (P/S) of CureVac is currently 10.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CureVac stock.
The Eulerpool Quality Score for CureVac is 4/10.
The ISIN of CureVac is NL0015436031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CureVac is A2P71U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CureVac is CVAC. The ticker symbol is used to trade CureVac shares on the stock exchange.
CureVac paid dividends every year for the past 0 years.
CureVac is assigned to the 'Health' sector.
The dividends of CureVac are distributed in EUR.
CureVac stock
CureVac Peer Group
CureVac Ticker
CureVac FIGI
All fundamentals and in-depth analysis of CureVac
Our stock analysis for CureVac stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.